Core Viewpoint - The article discusses the revolutionary shift in small nucleic acid drugs, highlighting their potential to transition from symptomatic treatment to addressing root causes, marking a significant advancement in the pharmaceutical industry [4]. Group 1: Small Nucleic Acid Drug Technology - Small nucleic acid drugs (siRNA, ASO, etc.) are considered the "third wave" of drug development, following small molecules and antibody drugs [4]. - These drugs are not limited by their molecular structure and can target a broader range of disease pathways, significantly increasing the probability of successful drug development [4]. - Current advancements in delivery technologies and chemical modifications have led to extended half-lives for these drugs, improving patient compliance in chronic disease management [4]. Group 2: Market Growth and Commercialization - The global small nucleic acid drug market is projected to reach $20.6 billion by 2029 and $54.9 billion by 2034, with a compound annual growth rate (CAGR) of 21.6% [5]. - Major players like Alnylam, Ionis, and Arrowhead are leading the market, with multinational corporations (MNCs) such as Novartis and Roche investing heavily in this sector [5]. - Alnylam's core product, Amvuttra, is expected to exceed $2 billion in sales by 2025, indicating strong market performance [6]. Group 3: Technological Breakthroughs - Arrowhead has developed RNAi therapies targeting various diseases through its TRiM platform, expanding the application of small nucleic acid drugs beyond liver diseases [7]. - Avidity Biosciences has made significant progress in muscle tissue delivery using antibody-oligonucleotide conjugates (AOC) technology, indicating a broader therapeutic potential [7]. Group 4: China's Small Nucleic Acid Drug Industry - The Chinese small nucleic acid drug industry is experiencing a qualitative leap, overcoming delivery patent barriers and demonstrating global competitiveness in target selection and molecular design [8]. - A complete industrial chain has emerged in China, with domestic raw materials achieving localization, thus reducing R&D costs [8]. - Significant business development (BD) transactions have occurred, including a record $5 billion deal between Wobang Pharmaceutical and Novartis, showcasing the global recognition of Chinese innovation [8].

Investment Rating - The report maintains an "Overweight" rating for the small nucleic acid drug industry [1] Core Insights - The small nucleic acid drug sector is experiencing a paradigm shift from "symptomatic treatment" to "root cause treatment," marking it as the "third wave of pharmaceutical innovation" following small molecules and antibody drugs. This innovation is driven by the ability of RNA drugs to overcome traditional drug development limitations, significantly expanding target ranges and improving drug development efficiency [4][5] - The global small nucleic acid drug market is projected to reach USD 20.6 billion by 2029 and USD 54.9 billion by 2034, with a compound annual growth rate (CAGR) of 21.6%, indicating high growth potential [5] - The industry is entering a commercialization phase, with key players like Alnylam, Ionis, and Arrowhead leading the market, supported by significant investments from multinational corporations (MNCs) [5] Summary by Sections Market Growth and Trends - The small nucleic acid drug market is expected to see rapid expansion, particularly in the fields of rare diseases and major diseases such as cardiovascular and metabolic disorders [5] - Alnylam's core product, Amvuttra, is projected to exceed USD 2 billion in sales by 2025, contributing to the company's profitability [5] - Domestic companies in China are overcoming delivery technology barriers and demonstrating global competitiveness in target selection and molecular design [7] Technological Advancements - Breakthroughs in delivery technologies and chemical modifications are enhancing the efficacy and half-life of small nucleic acid drugs, improving patient compliance in chronic disease management [4][5] - Arrowhead's TRiM platform has successfully developed RNAi therapies for various diseases, expanding the application of small nucleic acid drugs beyond liver diseases [5] Industry Ecosystem - The domestic small nucleic acid drug industry has established a complete industrial chain, with upstream raw materials achieving localization, thus reducing research and development costs [9] - Significant business development (BD) transactions have occurred, with notable collaborations between Chinese companies and global pharmaceutical giants, marking a historic high for the industry [9]

Core Viewpoint - The article highlights the successful IPO of Rebio Biotech (6938.HK), marking it as the first small RNA drug company listed on the Hong Kong Stock Exchange, with an opening price increase of over 23% and a market capitalization of HKD 11.8 billion [2]. Group 1: Company Overview - Rebio Biotech was founded in 2007 by Liang Zicai, who has extensive experience in the small RNA field, having established an independent laboratory for small RNA research in 1998 [6][7]. - The company has developed a comprehensive R&D platform with proprietary technology, successfully advancing multiple products into clinical phase II trials [7]. - Rebio Biotech has established international R&D centers in Kunshan, Beijing, and Gothenburg, Sweden, demonstrating its capability in global clinical development [7]. Group 2: Investment Background - Lenovo Star became one of the earliest institutional investors in Rebio Biotech in 2015, investing USD 1 million in its Series A financing [5][9]. - The investment strategy of Lenovo Star has focused on early-stage technology and healthcare, allowing them to identify and support leading projects in the small RNA drug sector before it gained significant attention [10]. - Over the years, Rebio Biotech has received support from various venture capital and private equity firms, including IDG Capital and Huaxia Fund, contributing to its growth and development [9]. Group 3: Market Context - The small RNA drug sector was initially considered less attractive, with only one drug approved before 2016, but it has since gained momentum following the approval of Biogen's Spinraza [9]. - The article emphasizes the growing interest and investment in the biopharmaceutical industry, particularly in regions like Suzhou, which has become a focal point for biotech investments [11]. - Lenovo Star's approach has evolved to focus on high-quality, cost-effective drugs and services, reflecting a shift in the healthcare investment landscape [12].

Consumer Insights - During the New Year holiday, 142 million domestic trips were made, representing a year-on-year increase of 5.19% compared to 2024, with total spending reaching 84.789 billion yuan, up 6.35%[16] - Hainan's duty-free shopping saw a significant boost, with the number of shoppers increasing by 27.09% and total spending rising by 49.89% compared to the same period in 2024[18] - In major cities, Shanghai's daily average consumption during the holiday was 12.2 billion yuan, a 2.5% increase year-on-year, while Beijing's monitored sales reached 4.04 billion yuan, up 16.3%[17] High-end Manufacturing - The "Justice Mission-2025" military exercise highlights the strategic importance of the military-industrial sector amid geopolitical tensions, emphasizing its role in national sovereignty and external risk management[20][26] - The military exercise's focus on Taiwan reflects a more precise and targeted approach compared to previous drills, enhancing control over critical maritime routes and deterring external interference[22] Hard Technology - Major domestic wafer manufacturers are actively engaging in capital operations, with SMIC's registered capital increasing from $6.5 billion to $10.0773 billion, and a planned acquisition of 49% of SMIC North for 40.601 billion yuan[27][33] - Longxin Technology's IPO aims to raise 29.5 billion yuan, potentially becoming the second-largest fundraising in the Sci-Tech Innovation Board's history, supporting its expansion in memory chip production[27][31] Health Sector - Domestic small nucleic acid drug companies, such as Rebio and Bowang Pharmaceutical, are demonstrating strong R&D capabilities, with multiple products entering clinical phases and significant business development collaborations underway[35][36]

Group 1 - MiniMax has officially launched its IPO in Hong Kong, with a total of 25.39 million shares to be issued at a price range of HKD 151 to HKD 165 per share, aiming to raise funds for AI model and product development [1] - MiniMax is recognized as one of the "top four global full-modal companies," with a user base exceeding 200 million, covering both B2C and B2B AI native products [1] Group 2 - Rebio Biotech has initiated its IPO in Hong Kong, planning to issue 27.49 million H-shares at a price of HKD 57.97 per share, with 10% allocated for Hong Kong and 90% for international sales [2] - The company focuses on small nucleic acid drug research, particularly in siRNA therapies, with its core product RBD4059 aimed at treating thrombotic diseases [2] Group 3 - BlueFocus Communication Group has submitted its second listing application to the Hong Kong Stock Exchange, with a focus on providing technology-driven marketing services across various industries [3] - The company aims to leverage its position as a leading marketing firm in China to enhance its global and AI-native business through the upcoming IPO [3] Group 4 - Longqi Technology has passed the listing hearing at the Hong Kong Stock Exchange, being recognized as a leading provider of smart products and services, with significant market shares in both consumer electronics and smartphone ODM sectors [4] - The company holds a 22.4% market share in the global consumer electronics ODM market and a 32.6% share in the smartphone ODM market, indicating its strong industry position [4]

Core Viewpoint - The launch of Rebio Biotech on the Hong Kong Stock Exchange marks a significant entry into the Chinese innovative drug industry, particularly in the small RNA field, with a share price set at HKD 57.97 and a listing date of January 9, 2026. The company has attracted notable institutional investors, indicating strong market interest [1][2]. Group 1: Industry Context - The global pharmaceutical innovation is transitioning into the "nucleic acid era," with small RNA drugs emerging as a disruptive treatment paradigm, following small molecules and antibody drugs [1]. - The industry is at a critical turning point, moving from "scientific breakthroughs" to "commercial realization," particularly in the siRNA sector [3]. Group 2: Company Positioning - Rebio Biotech is one of the few companies globally with comprehensive self-research capabilities in small RNA drugs, covering the entire process from target discovery to clinical development [1]. - The company has established a fully autonomous research and production platform, positioning itself to compete internationally and define new treatment standards [1][6]. Group 3: Product Pipeline and Validation - The company’s core products, RBD4059 and RBD5044, are strategically positioned in validated therapeutic areas, reducing development risks and enhancing commercial prospects [10][11]. - RBD4059 targets coagulation factor XI (FXI) and aims to transform anticoagulation therapy, while RBD5044 targets APOC3 for treating hypertriglyceridemia, benefiting from established regulatory pathways [10][11]. Group 4: Technological and Operational Strengths - Rebio's proprietary delivery systems, such as RiboGalSTAR™, have been clinically validated, providing a competitive edge and expanding the application of siRNA therapies beyond liver diseases [9]. - The company has established a clinical trial base in Sweden, ensuring compliance with international standards and facilitating entry into major markets [13]. Group 5: Financial Performance and Growth Potential - The company reported a revenue of CNY 104 million in the first half of 2025, a year-on-year increase of 56.57%, with a reduction in losses by 30.94%, indicating accelerating commercialization capabilities [6]. - The upcoming IPO funding will primarily support global clinical research for core products and enhance technology platform development, facilitating the transition from clinical to commercial stages [18][20]. Group 6: Strategic Collaborations - Rebio has secured strategic partnerships with leading pharmaceutical companies, which not only provide funding but also validate its technological capabilities [14]. - The company retains rights to overseas markets in its licensing agreements, highlighting its focus on global value realization [14]. Group 7: Future Outlook - The dual strategy of advancing proprietary products and engaging in platform licensing is expected to create a sustainable revenue model, enhancing financial stability and supporting ongoing research [17][18]. - Rebio Biotech is positioned for a systematic value reassessment as it combines technology, product pipeline, and international operational capabilities, making it a unique player in the biotechnology sector [20].

Core Insights - In 2025, China's pharmaceutical and healthcare industry enters a critical phase driven by "innovation deepening + global breakthrough," with emerging therapies like small nucleic acids, PROTAC, and CGT accelerating from clinical validation to commercialization [2][34] - The reports from the top ten Chinese securities firms provide authoritative insights into technological iterations, industry trends, and globalization strategies, serving as a guide for industry practitioners and investors [2][34] Group 1: Small Nucleic Acids - 2025 is a pivotal year for small nucleic acid drugs, driven by technological breakthroughs and expanding indications from rare diseases to chronic diseases like hyperlipidemia and hypertension [4][36] - The small nucleic acid sector is expected to see a surge in catalysts, including the commercialization of major products like Novartis' Inclisiran and the approval of Alnylam's Vutrisiran and Fitusiran [5][37] - The market for small nucleic acids is projected to reach approximately $30 billion, with significant growth anticipated in CNS diseases [10][42] Group 2: Brain-Computer Interface - The brain-computer interface industry is accelerating innovation with three main technical paths: invasive, semi-invasive, and non-invasive, each with distinct advantages and challenges [7][39] - The global brain-computer interface market is expected to reach approximately $2.6 billion by 2024, with a CAGR of about 13% from 2023 to 2027 [7][39] Group 3: PROTAC - PROTACs are gaining traction as targeted protein degradation drugs, with advantages such as high oral bioavailability and broad target range, making them popular in oncology and autoimmune disease research [19][51] - The first BTK PROTAC has entered Phase III trials, showcasing promising efficacy and safety data [19][51] Group 4: Chinese Innovative Drugs - Chinese innovative drugs are entering a "DeepSeek" moment, with domestic companies increasingly recognized overseas, and the number of license-out projects surpassing license-in projects for the first time in 2023 [16][48] - The market for innovative drugs in China is expected to exceed 2 trillion RMB by 2030, with a CAGR of 24.1% [29][63] Group 5: Peripheral Intervention Industry - The peripheral intervention industry is experiencing rapid growth, with a significant patient base and low treatment penetration compared to international standards [25][57] - The market for peripheral artery interventions is projected to grow at a CAGR of 15.6% from 2021 to 2030, while peripheral venous interventions may see a CAGR of 29.3% [25][57] Group 6: Weight Loss and Diabetes Treatment - The market for GLP-1RA drugs, such as semaglutide and tirzepatide, is expected to exceed $150 billion by 2031, with significant business development opportunities emerging for domestic companies [26][58] - Multi-target drug development is anticipated to overcome the limitations of single-target therapies, enhancing efficacy in weight loss and metabolic health [26][58]

Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - By 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Core Viewpoint - The pharmaceutical sector experienced a strong rally on the 26th, particularly in innovative drugs and vaccine concepts, with several companies seeing significant stock price increases [1] Industry Summary - Recent advancements in the small nucleic acid drug field have garnered significant attention from both the industry and investors, marking a transition from concept validation to the brink of industrial rise [1] - Since 2025, breakthroughs in delivery technology are expected to expand indications from the liver to cardiovascular and CNS areas, coupled with the commercialization of major products and substantial mergers by multinational pharmaceutical giants, indicating a golden development period driven by "technological breakthroughs + commercial realization" [1] - According to Everbright Securities, domestic pharmaceutical companies are accelerating their R&D progress, with many entering clinical research phases since 2025. The focus should be on leading innovative drug companies with advanced technology platforms and differentiated pipelines, as well as innovative industry chain companies likely to benefit from the overall industry upturn [1] - The investment approach in the pharmaceutical sector should increasingly emphasize the clinical value logic, addressing clinical needs of patients and doctors, influenced by domestic medical insurance policies and global expansion strategies, which are assigning higher premiums to clinical value [1] - From the perspective of clinical value, the innovative drug industry chain and innovative medical devices are viewed positively [1]

Group 1: Fixed Income Market - The main economic indicators weakened in October, leading to expectations of interest rate cuts and reserve requirement ratio reductions to support the economy [7] - The three pillars supporting the economy are under pressure, with negative growth in infrastructure and real estate investments [7] - The central bank has indicated the need for counter-cyclical and cross-cyclical adjustments, suggesting that policy rate cuts and new tools may be key to economic support in the coming months [7] Group 2: Pharmaceutical Industry - The small nucleic acid drug market is expected to grow significantly, with a projected market size of approximately $62 billion in 2024 and $467 billion by 2033, reflecting a compound annual growth rate of 25% [12] - Alnylam Pharmaceuticals is a leader in the siRNA field, with strong commercialization performance and a revenue of $2.617 billion in the first three quarters of 2025, a 58% year-on-year increase [13] - The industry is characterized by a high degree of activity in business development transactions, with over $45 billion in cumulative transactions in the siRNA sector from 2018 to November 2025 [12] Group 3: Consumer Electronics - The 2025 "Double Eleven" shopping festival saw a total e-commerce sales of 1.695 trillion yuan, a year-on-year increase of 14.2%, with the home appliance sector showing resilience and growth [14][15] - Home appliances accounted for 266.8 billion yuan in sales during the event, representing a 38.2% increase year-on-year, indicating a shift towards smart and integrated appliances [15] - Companies like Haier, Midea, and TCL achieved significant sales milestones, with over 10 billion yuan in transactions during the festival [15] Group 4: Transportation Industry - The express delivery sector experienced record volumes during the "Double Eleven" period, with 13.938 billion packages collected, marking a 117.8% increase in daily average volume compared to regular operations [20] - The oil transportation market is expected to strengthen in December, with VLCC daily earnings reaching $124,000, the highest since Q2 2020, driven by increased demand from the Middle East and Brazil [22] - The logistics sector is benefiting from improved collaboration with e-commerce platforms, enhancing operational efficiency and supporting consumer demand [20] Group 5: Precious Metals - The precious metals market is poised for potential upward movement, with gold prices recently rebounding but not surpassing previous highs, influenced by the end of the U.S. government shutdown and upcoming economic data releases [36][38] - Gold and silver prices have shown recent increases, with gold reaching $4,071.10 per ounce and silver at $52.01 per ounce, reflecting market reactions to economic conditions [35] - The market is closely monitoring key upcoming economic reports, including non-farm payrolls and GDP revisions, which could impact precious metal prices [38]